about
Exercise training, lymphocyte subsets and their cytokines production: experience of an Italian professional football team and their impact on allergy.Successful treatment of chronic mucocutaneous candidiasis caused by azole-resistant Candida albicans with posaconazole.Overexpression of the Cytokine BAFF and Autoimmunity RiskBiological treatments for SAPHO syndrome: an update.Biologics for ANCA-associated vasculitis.EAACI IG Biologicals task force paper on the use of biologic agents in allergic disorders.SAPHO Syndrome: Current Developments and Approaches to Clinical Treatment.Systemic lupus erythematosus occurring in a patient with Niemann-Pick type B disease.Genetic variants regulating immune cell levels in health and disease.Characterization of patients with angioedema without wheals: the importance of F12 gene screening.The salivary proteome profile in patients affected by SAPHO syndrome characterized by a top-down RP-HPLC-ESI-MS platform.Identification of a novel and recurrent mutation in the SERPING1 gene in patients with hereditary angioedema.Mutation of the angiopoietin-1 gene (ANGPT1) associates with a new type of hereditary angioedema.A promising new treatment for SAPHO syndrome that deserves further studiesIdiopathic pyoderma gangrenosum: successful resolution with infliximab therapy and pro-inflammatory cytokines assessmentSwitch to icatibant in a patient affected by hereditary angioedema with high disease activity: a case reportTH17 cells are increased in the peripheral blood of patients with SAPHO syndromeEfficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthmaEfficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthmaEfficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines-Recommendations on the use of biologicals in severe asthmaThe role of genetics in the current diagnostic workup of idiopathic non-histaminergic angioedemaEAACI Biologicals Guidelines - Recommendations for severe asthmaConsiderations on Biologicals for Patients with allergic disease in times of the COVID-19 pandemic: an EAACI StatementProteomic Analysis of the Acid-Insoluble Fraction of Whole Saliva from Patients Affected by Different Forms of Non-histaminergic Angioedema
P50
Q33891349-8F134001-5E37-461D-8173-2306F262ACAEQ34415094-3096DF49-D5A2-4B7D-BA2B-BBCECC5ECE07Q34555873-6F6FC193-7B7C-406B-99AF-3F8504E3721DQ38213295-AC27D222-9710-4A15-8997-1AC560626B3FQ38226676-2FFD5B6B-2744-4391-9B59-D77F4C56F24FQ38394577-52EC4886-0CCF-4F4C-848E-B37E92A05FD7Q38815965-AC0666EE-4703-4581-B232-7CF935403022Q40156333-973F3947-DEED-426A-8E59-4F88C1AB66ACQ41229283-4675A998-57A5-4008-B808-7B8090F45C9AQ41285230-2172E44E-F050-4A0F-8BF4-8FF88938D1EAQ41450571-353688E1-436A-418A-9186-A40F633B8006Q43910433-BCB5D6E9-2EB4-4C33-A994-2EDBEB226318Q50950631-95E21EA2-8CD9-44BF-8395-F6FE5B27C8B1Q57485608-5911C4D7-6233-4CB0-B7E7-6363F653BC67Q83577619-BBCB06C3-4652-4DED-82E9-2979976575A5Q83902470-B3E4C6F2-03F9-4C4D-803A-FC5840A8218CQ87653914-FE6F41A2-9E29-44AC-B1C1-F51DBCC3E157Q89605999-7D16314D-4586-4B7D-A07A-BDB99779B356Q89739188-5634C5A4-B801-4437-9E13-5FD847546816Q90185425-47475F3E-0DC6-4873-A901-18C3F5801554Q93026558-47F25C95-11A0-43A5-8783-D690BAF0D792Q96138249-D3E2C0C7-87B8-4EDF-94C7-9C0EC58C7B44Q96158875-A3E37BC3-DDBB-4721-B4F5-F285E7B07708Q96233160-74823E17-9266-485D-8635-157CAC537D6F
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Davide Firinu
@ast
Davide Firinu
@en
Davide Firinu
@es
Davide Firinu
@nl
Davide Firinu
@sl
type
label
Davide Firinu
@ast
Davide Firinu
@en
Davide Firinu
@es
Davide Firinu
@nl
Davide Firinu
@sl
prefLabel
Davide Firinu
@ast
Davide Firinu
@en
Davide Firinu
@es
Davide Firinu
@nl
Davide Firinu
@sl
P106
P1153
23008107600
P21
P31
P496
0000-0002-5768-391X